Sodium phosphate (bowel prep)

osmotic saline laxative, colon cleansing

Also sold as OsmoPrep, Visicol, Fleet Phospho-soda.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Oral sodium phosphate is not a classical depletion drug. It is a one-day, two-dose osmotic purgative (32 tablets, 48 g sodium phosphate) that delivers a large absorbed phosphate load, which the kidney must excrete [1][2]. The label describes no metabolism, no CYP effect and no nutrient-absorption mechanism in the sections retrieved, and the only elimination fact given is that inorganic phosphate is excreted almost entirely by the kidneys [1]. The nutrient signals are therefore acute procedural electrolyte shifts that lasted about a week or less in the studies that followed patients [9]. They are mostly drug toxicity or excess, and none of them is a dietary deficiency that more intake would fix.

osmotic saline laxative, colon cleansing · ATC A06AD17 (WHO ATC/DDD Index [3]) · also sold as OsmoPrep and Visicol (tablets); Fleet Phospho-soda (oral solution) · reviewed 2026-10-06. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Sodium phosphate (bowel prep) in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Phosphate: EXCESS load, acute, 1 to 2 day window

Red — Severe

See study details

Oral sodium phosphate delivers an absorbed phosphate load that roughly doubles serum phosphate within hours and keeps it high for about a day. This is a drug-caused excess and renal-retention risk, not a deficiency.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Red

Limits on what this shows

At-risk subgroups: Label: older age, hypovolemia, increased bowel transit time, active colitis, baseline kidney disease, and use of medicines that affect renal perfusion or function [1]. Phosphate is higher at age 75 and over (8.0 versus 7.0 mg/dL) [2]. Pediatric safety under 18 not demonstrated [1].

Direction

EXCESS and retention. Not depletion. More phosphate intake is never the remedy.

Regulatory status

Boxed warning for acute phosphate nephropathy. Contraindicated with biopsy-proven or history of acute phosphate nephropathy [1][2]. The label states patients with renal disease may have difficulty excreting a large phosphate load [1].

Population evidence

Label pharmacology, 23 healthy subjects: 4.0 to 7.7 mg/dL at 3 hours and 8.4 mg/dL after dose 2, median 24 hours elevated [1][2]. Meta-analysis of 13 randomized trials (2,773 patients, 1,378 on sodium phosphate tablets versus 1,395 on PEG lavage): serum phosphorus rose more with the tablets, mean difference 4.51 mg/dL (95% CI 2.9 to 6.11, P under 0.00001) [6]. Cohort of 100 colonoscopy patients: 45% had elevated serum phosphate, correlated with creatinine and age, and higher in users of ACE inhibitors, AT2 antagonists or diuretics [8]. 36 hospitalized elderly patients: the phosphorus rise correlated inversely with creatinine clearance (R -0.52, P =.001) [7]. Randomized trial in subjects with eGFR 60 or above who committed to hydration: significant phosphate increase, normal in all by 1 week, and no acute kidney failure in either arm [9]. 2,270 health-exam participants: hyperphosphatemia more prevalent after phospho-soda than PEG [11].

Mechanism

Named. The phosphate salt is absorbed from the gut and cleared by the kidney, so the rise is larger when renal clearance is lower [1][7]. Fractional urinary phosphorus excretion tripled by day 2 in the elderly series [7].

Outcome, not a nutrient

Acute phosphate nephropathy is a kidney injury (calcium phosphate deposition) and is filed here as an outcome of the excess, not as a nutrient entry (Hard Rule 2). Biopsy series, 21 normocalcemic patients after oral sodium phosphate solution or Visicol tablets (from a pool of 31 nephrocalcinosis biopsies in 7,349): mean age 64, 81% female, 16 hypertensive with 14 on ACE inhibitors or ARBs; 4 needed permanent hemodialysis and 17 developed chronic renal insufficiency [4]. The abstract does not split cases between solution and tablets.

Counter-evidence held on record

Counter-evidence and confounding The size of the kidney outcome is contested. Hurst 2007 (9,799 patients): acute kidney injury in 1.16%, oral sodium phosphate odds ratio 2.35 (1.51 to 3.66) [12]. Russmann 2007 (2,352 patients): renal dysfunction relative risk 1.13 (0.58 to 2.23) versus PEG [13]. Layton 2014: AKI 0.2% on sodium phosphate versus 0.3% on PEG, adjusted hazard ratio 0.86 (0.75 to 0.99) [14]. These three are abstract-level reads via a listing page. Case series such as Markowitz [4] have no comparator. The phosphate rise itself is not contested; the kidney consequence in unselected patients is. Several included trials in [6] used tablets, but product-level identity (OsmoPrep or Visicol) was not given in the abstract. Framing caution This is an excess and retention risk. Do not add phosphate, and avoid extra sodium phosphate products around the prep (the label warns that added sodium phosphate purgatives or enemas may raise nephropathy risk [2]). Whether to use or avoid this prep is a prescriber decision.

Potassium: transient hypokalemia in the prep window, resolving within about a week

Orange — Moderate

See study details

Sodium phosphate prep lowers serum potassium more often than PEG prep, in a bounded window around the procedure, and the studies that rechecked found normal values by 1 week.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

Null findings: Meta-analysis reported no major complications [5]. The 100-patient cohort reported significant disturbance "without overt clinical effects" [8].
At-risk subgroups: Elderly, cognitively impaired or dependent patients with severe diarrhea [7]; people on medicines that raise fluid and electrolyte risk, which the label names as diuretics, ACE inhibitors and ARBs [2].

Direction

Acute loss (disturbance during purgation), not a dietary deficiency.

Regulatory status

Hypokalemia is named in the label as an electrolyte abnormality linked to seizures and to QT prolongation; no incidence is given [1][2].

Population evidence

Meta-analysis, 13 studies and 2,386 patients: hypokalemia in 17.2% on sodium phosphate versus 4.8% on PEG; potassium fell more with sodium phosphate (mean difference -0.38, P under 0.001) [5]. Meta-analysis of 13 randomized trials of sodium phosphate tablets: potassium fell in both arms, more with tablets, mean difference 0.38 mEq/L (95% CI 0.13 to 0.62, P = 0.006) [6]. 100 colonoscopy patients: 26% hypokalemia [8]. 36 elderly inpatients: 56% hypokalemia, higher in demented patients [7]. Randomized trial: significant fall, back to normal by 1 week [9]. 2,270 health-exam participants: hypokalemia more prevalent after phospho-soda than PEG [11].

Mechanism

Inference, not directly tested in the sources opened: fluid and electrolyte loss through osmotic diarrhea. The elderly series found urinary potassium excretion unchanged, which is consistent with a gut rather than renal route [7]. PEG also lowers potassium in the same trials [6], so this is not specific to phosphate.

Counter-evidence held on record

Counter-evidence and confounding Baseline potassium, diet, vomiting and diarrhea severity differ between patients and were not adjusted in these abstracts. The meta-analyses compare against PEG, an active comparator that also lowers potassium, so they measure the added effect of sodium phosphate rather than effect versus no prep. Study quality was rated low in [6]. Orange rather than red because the effect is bounded to the prep window and mostly asymptomatic. Framing caution This is a short-lived, procedure-linked shift. It is not a reason to start a potassium supplement. Any correction belongs with the prescriber, especially in people with kidney disease.

Calcium: secondary transient fall that tracks the phosphate rise, not a dietary deficiency

Orange — Moderate

See study details

Serum calcium falls after sodium phosphate prep, more than after PEG, in step with the phosphate rise. It recovered within a week in the trial that rechecked.

Full detail and limits

Limits on what this shows

Null findings: The pooled difference is small (0.41 mg/dL) and most patients had no symptoms [6][8]. The randomized trial reported values back within normal limits in all subjects by 1 week [9].
At-risk subgroups: Older adults and people with lower renal clearance, in whom phosphate rises more [7][8]; the case report patient had no renal impairment or prior electrolyte disorder, so severe cases can occur without those risks [21].

Direction

Secondary disturbance caused by phosphate excess. Not calcium deficiency and not bone loss.

Regulatory status

Hypocalcemia is named in the label as linked to seizures and QT prolongation; the label gives no calcium percentages [1][2].

Population evidence

Meta-analysis of 13 randomized trials of sodium phosphate tablets: calcium fell in both arms, more with tablets, mean difference 0.41 mg/dL (95% CI 0.04 to 0.77, P = 0.03) [6]. 36 elderly inpatients: hypocalcemia in 58% [7]. 100 colonoscopy patients: 16% hypocalcemia, with a negative association between phosphate and calcium [8]. 1996 series in patients with normal creatinine: about 6% had calcium under 8.0 mg/dL (listing-level line, secondhand) [10]. Randomized trial: significant decrease, normal by 1 week [9]. 2,270 health-exam participants: hypocalcemia more prevalent after phospho-soda [11]. Case report of an 85-year-old man after Fleet Phospho-soda plus a phosphate enema: corrected calcium 1.33 mmol/L, QTc 642 ms [21].

Mechanism

Named by the case-report authors: absorbed phosphate causing secondary hypocalcemia [21]. The inverse phosphate-calcium association in [8] fits this. Parathyroid hormone was not reported in any source opened.

Counter-evidence held on record

Counter-evidence and confounding This entry shares its source studies with the phosphate and potassium entries (see Overlap map). The case report is a single conference abstract. Orange rather than red because the average effect is small, transient and mostly asymptomatic. Framing caution This is a secondary fall driven by phosphate excess. It does not mean calcium intake is low, and calcium supplements are not recommended from this entry. Symptomatic cases (tingling, cramps, palpitations) need clinical assessment.

Magnesium: label-named risk and one case report, no cohort measurement retrieved

Yellow — Low

See study details

Hypomagnesemia is named as a possible electrolyte disturbance on the label and appears in one case report after Fleet Phospho-soda, but no cohort measuring magnesium after sodium phosphate prep was opened.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

Null findings: None retrieved; no controlled magnesium measurement for sodium phosphate was located.
At-risk subgroups: Not established.

Direction

Acute low serum level (disturbance), not a dietary deficiency.

Regulatory status

Label lists hypomagnesemia among electrolyte abnormalities associated with seizures (and, in the current label, cardiac complications), with no incidence or numbers [1][2].

Population evidence

One case report (Tier B): 85-year-old man, Fleet Phospho-soda plus phosphate enema, corrected calcium 1.33 mmol/L, phosphate 3.38 mmol/L, magnesium 0.55 mmol/L as reported, QTc 642 ms [21]. A 2002 Surgery record titled "Significant hypomagnesemia after celiotomy: implications of preoperative bowel cleansing with sodium phosphate purgative" was found by title but its abstract could not be read, so it is not used [22]. The tablet meta-analysis reported no magnesium data [6].

Mechanism

Not stated in any source opened. Any proposed route (gut loss, phosphate binding of divalent cations) would be inference only.

Counter-evidence held on record

Counter-evidence and confounding The case report patient also had low calcium and a long QTc, so magnesium cannot be separated from the calcium and phosphate disturbance (see Overlap map). A conference abstract was read, not a full paper. Framing caution A monitoring prompt only, for people with symptoms or QT concerns. It is not a magnesium deficiency claim and does not support supplementation.

Sodium and fluid shifts: mixed direction, magnitude not retrieved

Yellow — Low

See study details

Studies report sodium rising after sodium phosphate prep, while the label also lists hyponatremia and low serum osmolality in its seizure warning, and fluid shifts have caused fatalities.

Full detail and limits

Limits on what this shows

Null findings: No acute kidney failure in the trial with hydration [9]. Magnitude and clinical effect of the sodium change were not retrieved.
At-risk subgroups: Hypovolemic, elderly and renal patients per the label's fluid and electrolyte warnings [1].

Direction

Mixed. Excess (hypernatremia) is what the studies report; the label also names hyponatremia. Neither is a dietary issue.

Regulatory status

Label: sodium phosphate products before colonoscopy "resulted in fatalities due to significant fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias"; seizures linked to hyponatremia and low serum osmolality [1][2].

Population evidence

Randomized trial of oral sodium phosphate solution versus PEG: significant increases in serum sodium (and phosphate), returning to normal limits by 1 week [9]. 2,270 health-exam participants: hypernatremia more prevalent after phospho-soda than PEG [11]. Effect sizes for sodium were not in the abstract-level text read.

Mechanism

Not stated in the sources opened. The regimen delivers a sodium load by design (sodium phosphate salt, 48 g) [1].

Counter-evidence held on record

Counter-evidence and confounding Direction is inconsistent between the studies (up) and the label's warning (down, in the seizure context), and the size of the sodium change was not available. Held at yellow as a context flag. Framing caution Not a sodium deficiency or a prompt to change sodium intake. Hydration around the prep is a prescriber and label matter.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

See study details

No sodium phosphate bowel prep study of mitochondrial structure, electron transport or biogenesis was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C source was opened to support yellow, and no circulating claim of sodium phosphate mitochondrial damage was found on the consumer pages opened ([23][24][25]) to rebut. This is a disclosed gap, not a finding of safety. Probably genuine thin literature plus tooling limits; re-check when PubMed and OpenAlex access returns.

What was searched

Crossref bibliographic search "sodium phosphate purgative mitochondria ATP oxidative stress colon" returned 8 records: three bowel-prep nephropathy or hypomagnesemia records, a 1956 mitochondrial phosphate-exchange biochemistry paper that is not a drug study, and unrelated mitochondrial or cancer papers; none studied sodium phosphate prep and mitochondria [titles only]. PubMed listing "sodium phosphate laxative mitochondrial ATP": 429, not read. Repair pass 2026-10-07: web search "sodium phosphate bowel cleansing mucosal ATP mitochondria colonocyte energy metabolism" returned bowel-prep efficacy and electrolyte papers, none on mitochondria or ATP (titles and snippets only, none opened as evidence); Crossref "bowel preparation sodium phosphate mitochondrial ATP energy" and OpenAlex "sodium phosphate bowel preparation mitochondria" both returned 429. The rat studies that measured tissue MDA, SOD, GSH-Px or catalase [26][27] are oxidative stress endpoints and did not measure mitochondrial structure, respiration or biogenesis, so they are not used here. Label sections retrieved: no mitochondrial content [1][2].

Channel outcomes

Dedicated web search for this category was not possible in the original review (search budget exhausted); one search ran in the repair pass and then the budget ran out again. PubMed and PMC article pages: bot-verification. Crossref and OpenAlex: several 429 responses. DailyMed and Drugs.com label pages: opened. Mixed result: one clean zero on an open channel plus tooling-limited access to the main literature databases.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress: local colonic tissue signal in rats, serum markers null in one small human trial

Yellow — Low

See study details

In rats, sodium phosphate bowel washout raised colonic tissue malondialdehyde and mucosal damage more than PEG or tap water. A second rat model found higher catalase activity, and a small randomized human thesis found no difference in serum oxidative stress markers between preps.

Full detail and limits

Limits on what this shows

Null findings: No between-group difference in serum TAS, TOS, OSI or IL-6 in the human thesis, whose authors concluded no obvious effect on systemic oxidative stress [28]. A rat TNBS-colitis study comparing sodium phosphate, PEG-electrolyte and saline found no significant macroscopic or microscopic difference and did not measure oxidative markers [31].
At-risk subgroups: Not established.

Direction

Mixed and local. The main finding is drug-caused tissue oxidative injury in the colon (toxicity, Hard Rule 2), not an antioxidant nutrient deficiency. One rat study ran the other way (higher antioxidant enzyme activity, a protective-direction signal in an ischemia model).

Regulatory status

Not mentioned in the label sections retrieved [1][2].

Population evidence

Tier B, animal, sodium phosphate in the cohort. Coskun 2001 (British Journal of Surgery): 30 Wistar rats in three groups (PEG, sodium phosphate, tap water), colon sampled after 8 hours. Mucosal damage was greater with both preps than control and worse with sodium phosphate than PEG. Tissue MDA was significantly higher in both prep groups than control and higher with sodium phosphate than PEG. SOD and GSH-Px differed significantly only between control and both prep groups; the direction and numbers were not in the abstract read [26]. Baca 2008 (American Journal of Surgery): 70 male Sprague-Dawley rats in 7 groups of 10, bowel preparation before left colon ischemia/reperfusion. The sodium phosphate group was among the two least histologically affected; catalase was higher than in the I/R control (P under.002), while Cu-Zn SOD was higher only in the mannitol group [27]. Human, Tier B-level (unreviewed thesis, abstract read): Coskun 2025, Bezmialem Vakif University, 76 patients randomized to PEG 3350, monobasic sodium phosphate, or sennoside A-B calcium. Changes in serum TAS, TOS, OSI and IL-6 did not differ between groups (P over.05). Sigmoid biopsy tissue TOS differed across the three solutions overall (P =.043) but pairwise comparisons were not significant (sennoside versus sodium phosphate P =.054). The abstract does not give the sodium phosphate formulation or dose [28].

Mechanism

Proposed by the rat-study authors as mucosal injury with lipid peroxidation (MDA) and a change in antioxidant enzymes [26]. Not tested in humans, and a phosphate-specific route was not examined in any source opened.

Counter-evidence held on record

Counter-evidence and confounding PEG also raised tissue MDA in [26], so the effect is not specific to phosphate, and the comparison is against water and PEG, not against no prep in humans. The rat dose relative to the human regimen, the sodium phosphate product, and the SOD and GSH-Px direction were not retrieved. The tissue signal is colonic and local; the only human systemic measurement was null [28]. The mixed direction between [26] and [27] and the model differences (healthy colon versus ischemia/reperfusion) limit interpretation. Held at yellow because the evidence is animal and mechanistic, with one unreviewed human thesis. See the Overlap map for how this entry relates to the Mitochondrial burden and ATP gaps. Framing caution This is a possible drug-induced local tissue effect, not a deficiency of any antioxidant nutrient. It does not support antioxidant or vitamin supplementation, and it is not a customer-facing deficiency claim.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No copper measurement after sodium phosphate bowel prep was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence, and no circulating copper claim found for this drug on the pages opened. Copper is kept as its own entry and is not merged with iron. A disclosed gap, not a finding of safety.

What was searched

Crossref bibliographic "bowel preparation sodium phosphate serum iron ferritin copper zinc": 8 records, of which the only prep papers were a 2026 acute phosphate nephropathy case report (Cureus) and the Ainley 2005 electrolyte study [8]; the rest were unrelated trace-element papers. Another Crossref query combining iron, copper and trace elements returned 429. Ainley 2005 measured phosphate, calcium, potassium and creatinine, not copper (abstract level). Label sections: no copper content [1][2]. Repair pass 2026-10-07: web search "bowel preparation sodium phosphate serum copper zinc trace elements loss diarrhea purgative" returned bowel-prep reviews, patents and electrolyte papers, none on copper; OpenAlex "sodium phosphate bowel preparation copper zinc" returned 429. A sodium biphosphate versus mannitol trial (60 patients) listed its measured labs as sodium, potassium, calcium, magnesium, phosphorus, urea, creatinine, glucose, hematocrit, hemoglobin and osmolality, with no copper or iron [30]. Cu-Zn SOD activity in a rat study [27] is an antioxidant enzyme readout, not a copper status measure.

Channel outcomes

One open channel returned a clean zero; PubMed and other databases not readable. Likely a genuine gap with a tooling-limited component.

Iron

Not graded — disclosed evidence gap

See study details

No iron status measurement after sodium phosphate bowel prep was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence and no circulating iron claim found for this drug. Iron is a separate entry from Copper. A disclosed gap, not a finding of safety.

What was searched

Same Crossref query as Copper (no iron-after-prep study). Crossref "oral sodium phosphate colonoscopy preparation hemoglobin hematocrit anemia iron": 8 records, all prep efficacy or technique papers, none measuring iron or hemoglobin. Label sections and the three consumer pages opened mention no iron [1][2][23][24][25]. Repair pass 2026-10-07: web search "oral sodium phosphate colonoscopy preparation serum iron ferritin hemoglobin change before and after" led to two trials that measured hemoglobin and hematocrit but not iron ([29] opened in full abstract and methods; [30] abstract only), and to the tablet meta-analysis, which reported no iron or hemoglobin data [6]. A further Crossref query "sodium phosphate bowel preparation hemoglobin hematocrit iron" returned 8 prep papers and one unrelated dietary-iron paper, none measuring iron after sodium phosphate.

Channel outcomes

Two Crossref queries opened with nothing relevant; PubMed and PMC article pages not readable. Likely a genuine gap with a tooling-limited component. The prep is a one-day exposure, so a chronic iron-absorption mechanism is not expected, but no source opened tests this.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk: short-term composition shift in a subgroup, mostly recovered by day 28

Orange — Moderate

See study details

After oral sodium phosphate solution, stool microbiota composition and diversity shifted at day 7 in a subgroup of 20 men, while the dominant genera changed little by day 28.

Full detail and limits

Limits on what this shows

Null findings: Dominant genera little changed at day 28 [15]; no lasting effect for most subjects after PEG prep [18]; restoration within 14 days after Moviprep [17].
At-risk subgroups: Not established. Effects were larger in inflammatory bowel disease biopsies [16] and in the "Type 2" sample group in [15].

Direction

Compositional disturbance. Not a depletion of a nutrient, and no clinical outcome (infection, symptoms) was measured.

Regulatory status

Not mentioned in the label sections retrieved [1][2].

Population evidence

Chen 2018 (Tier A for this drug, oral solution form): 20 overweight Taiwanese men, split dose of Fleet Phospho-Soda with 3 to 4 L water, stool 16S sequencing before prep, day 7 and day 28. Dominant genera (Bacteroides, Prevotella) changed little by day 28. In "Type 2" samples, Shannon diversity differed between baseline and day 7 and four genera changed (Bacteroides, Prevotella, Oscillospira, Holdemania; P under 0.05); "Type 1" samples were stable [15]. A 2025 review of bowel-prep microbiome studies lists Chen 2018 as its only sodium phosphate study among 11 [19]. Shobar 2016: 18 subjects (10 healthy, 8 inflammatory bowel disease), of whom 7 used a sodium phosphate-based prep and 11 PEG; sampled a mean 4.0 to 4.4 days after prep; Shannon index fell in IBD biopsies (P = 0.025), phylogenetic diversity fell in healthy biopsies (P = 0.021), Bacteroidetes rose. Results were not stratified by prep type, so sodium phosphate was in the cohort but its share of the effect cannot be isolated [16].

CLASS EXTRAPOLATION (context only)

Jalanka 2015, 23 healthy volunteers, Moviprep (PEG with ascorbate): total bacterial load fell 31-fold, composition and load restored within 14 days, split dosing less disruptive [17]. O'Brien 2013, 15 patients, bisacodyl plus 2 L PEG: no greater variation than in unprepped controls for most subjects, short-term change in a few [18]. Li 2022, PEG in humans and mice: largest change at day 3, return toward baseline by day 28 at a "new homeostasis" [20]. Cohort test: sodium phosphate was NOT in the cohort of [17], [18] or [20]; these are Tier C, capped at yellow, and are used only to frame the recovery time scale, not to raise this grade.

Mechanism

Present but nonspecific: osmotic purgation flushes luminal contents, and all prep types appear to do this in the studies above. A phosphate-specific effect on bacteria was not studied in any source opened.

Counter-evidence held on record

Counter-evidence and confounding Chen 2018 is small, has a single homogeneous population (overweight men), no detailed diet record, relative abundance only, and it is not clear a concurrent unprepped control group was used (not stated in the page read). The product was the oral solution, not tablets, so formulation extrapolation applies. Graded orange only because a primary study with this drug in the cohort shows a real change bounded to a subgroup and a time window. Framing caution The customer string must carry the boundary: short-term, subgroup-specific, small study. This is not a claim of lasting dysbiosis, and it is not a basis for recommending probiotics.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No evidence was found that sodium phosphate bowel prep changes red-cell mass, oxygen-carrying capacity or tissue oxygen delivery. The one direct measurement located, hemoglobin and hematocrit before and after prep in an 80-patient randomized trial, showed no significant change.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence for this drug supporting a change in oxygen delivery, and no circulating oxygen-carrying claim found. The measured null in [29] (non-significant hemoglobin and hematocrit shift in a small trial with this drug in the cohort) is not evidence for a grade, and a non-significant rise would at most reflect hemoconcentration from fluid loss, a volume effect and not an oxygen-delivery deficiency (Hard Rule 2). Kept separate from ATP production. A disclosed gap, not reassurance.

What was searched

PubMed listing "sodium phosphate bowel preparation hemoglobin" (opened): 4 records, none about oxygen delivery with sodium phosphate. The one hemoglobin line in the listing concerned sodium picosulfate/magnesium citrate (hemoglobin rising with dehydration); that is a different drug, a volume effect and not an oxygen-delivery deficiency, and it was seen only as a listing summary, so it is not used. Crossref "oral sodium phosphate purgative oxygen delivery 2,3-diphosphoglycerate methemoglobin hemolysis": 8 records, only bowel-prep nephropathy, hypomagnesemia and syncope papers plus unrelated hemoglobin biochemistry, none about this drug and oxygen delivery. Label sections: none [1][2]. Repair pass 2026-10-07, measured null: Habr-Gama 1999 (Revista do Hospital das Clinicas), prospective randomized trial, 80 patients, 40 receiving 180 mL of a sodium phosphate preparation (monobasic 0.24 g/mL, dibasic 0.09 g/mL, two 90 mL doses, no brand named) versus 750 mL of 10% mannitol: hemoglobin and hematocrit were measured before and after prep and showed "a slight increase" in both groups, not significant (hemoglobin P = 0.16, hematocrit P = 0.36); per-group values were not in the text read, and the paper also measured sodium, potassium, phosphorus, calcium and osmolarity [29]. A 60-patient sodium biphosphate versus mannitol trial also measured hemoglobin and hematocrit, but its abstract does not give the results [30]. The tablet meta-analysis reported no hemoglobin or hematocrit data [6]. A search combining hemolysis, methemoglobinemia, oxygen saturation and 2,3-diphosphoglycerate could not be run because the web search budget ran out.

Channel outcomes

Two open channels with clean zeros on this question; article-level databases not readable. Likely genuine gap, with a tooling-limited component.

ATP production

Not graded — disclosed evidence gap

See study details

No study of cellular energy output or ATP synthesis after sodium phosphate bowel prep was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C evidence and no circulating ATP or "low energy" claim for this drug found on the pages opened. Kept separate from Mitochondrial burden and Oxygen delivery. A patient-facing electrolyte symptom list on a consumer page [24] includes "lack of energy"; that is a symptom of the electrolyte disturbance, not an ATP claim. A disclosed gap.

What was searched

Same queries as Mitochondrial burden (Crossref combined query opened; PubMed listing 429), plus the oxygen-delivery Crossref query above. No record linked oral sodium phosphate prep to ATP. Label sections: none [1][2]. Repair pass 2026-10-07: the web search "sodium phosphate bowel cleansing mucosal ATP mitochondria colonocyte energy metabolism" returned no ATP or energy-metabolism study of this drug (see Mitochondrial burden); Crossref and OpenAlex follow-ups returned 429. Terms not separately searched: respiration, membrane potential, adenine nucleotides.

Channel outcomes

Open channel returned a clean zero; main databases not readable. Tooling-limited plus probable genuine gap.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Gut microbiome: "bowel prep wipes out gut bacteria for good" (lasting dysbiosis)
Where it comes from: Consumer microbiome page that lists sodium phosphate and PEG together and cites a one-month effect from a single dissenting study [25] (Tier D).
Why it fails: For sodium phosphate itself, dominant genera changed little by day 28 and only a subgroup showed a day-7 shift [15]. Other prep types recovered within 14 to 28 days [17][20] or showed no lasting change for most subjects [18]. The one-month study the page cites was a PEG study seen only secondhand (primary not opened). The short-term change in [15] is graded orange; only the claim of lasting damage fails.
Gut microbiome: "probiotics are needed after sodium phosphate prep"
Where it comes from: Same page [25], citing a probiotic mixture trial of post-colonoscopy symptoms.
Why it fails: The probiotic trial the page cites was not opened, and nothing opened tests probiotics after sodium phosphate prep specifically. The page itself says the evidence is mixed. Unsupported for this drug at any tier.

How the body handles this medication

Metabolism and enzymes: Inorganic phosphate salt. No metabolism, CYP induction or CYP inhibition is described in the label sections retrieved; absence of a statement is not a finding of no effect.[1][2] DailyMed OsmoPrep label; Drugs.com label reproduction
Absorption and serum rise: In 23 healthy subjects, serum phosphorus rose from 4.0 (SD 0.7) mg/dL to 7.7 (SD 1.6) mg/dL at a median 3 hours after the first 30 g dose, and to 8.4 (SD 1.9) mg/dL at a median 4 hours after the second dose. It stayed elevated for a median 24 hours (range 16 to 48).[1][2] sec 12.3 / clinical pharmacology
Elimination: "The inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys." Patients with renal disease may have difficulty excreting a large phosphate load. The effect of renal impairment on pharmacokinetics has not been studied.[1][2]
Regimen and age effect: 32 tablets (48 g) as 20 tablets the evening before and 12 tablets 3 to 5 hours before the procedure, each 4-tablet aliquot with 8 oz clear liquid every 15 minutes. Mean colonoscopy-day phosphate: 7.0 mg/dL (age 18 to 64), 7.3 (65 to 74), 8.0 (75 and over).[1][2] dosing, geriatric use
Drug and product interactions: Oral medicines given close to a dose may not be absorbed because of rapid peristalsis and watery diarrhea; the current label says to give them at least 1 hour before or after starting each dose. Diuretics, ACE inhibitors, ARBs and possibly NSAIDs raise fluid, electrolyte and renal risk. Additional sodium phosphate purgatives or enemas may raise acute phosphate nephropathy risk. No vitamin or mineral interaction is listed.[1][2] sec 7
Product forms in the evidence: The label above is for the tablets. Several studies cited below used the oral solution (Fleet Phospho-soda), which has the same active moiety. Where a study used the solution, the entry says so.[15][9]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Before the prep
Kidney function and hydration
Creatinine or eGFR and volume status matter most, since phosphate is excreted almost entirely by the kidneys and the label lists age, hypovolemia, baseline kidney disease and colitis as risk factors [1][4]. Choosing a different prep in higher-risk patients is a prescriber decision.
Lab / at-risk groups
Phosphate, calcium, potassium
One cohort recommended baseline electrolytes in elderly patients and those with comorbidities before sodium phosphate prep [8]. Post-prep checks are reasonable where symptoms occur (tingling, cramps, palpitations, confusion, seizure) or in renal impairment.
Lab / unusual symptoms
Magnesium and ECG
Only if symptoms, a long QT or an unexplained low calcium occur; the evidence is one case report [21] and a label mention [2].
Medicines
Renal-risk drugs and other phosphate products
The label names diuretics, ACE inhibitors, ARBs and possibly NSAIDs as raising risk, and warns that added sodium phosphate purgatives or enemas may raise nephropathy risk [2]. Review these with the prescriber or pharmacist.
Timing
Supplement and medicine separation
Per the label, take oral medicines at least 1 hour before or 1 hour after starting each prep dose [2]. No mineral or vitamin timing interaction is listed. No supplement dose is recommended or appears anywhere in this dossier, so no upper-limit comparison was needed.
Populations
Age, pregnancy, pediatric
Phosphate is higher at age 75 and over (8.0 versus 7.0 mg/dL) [2]. Safety under 18 has not been demonstrated [1]. No pregnancy data exist to inform risk [2]. Gut microbiome: no routine test or probiotic is supported by this review.

Overlap map, to prevent double counting

Phosphate (red)
Shares evidence with: Calcium; Potassium; Sodium and fluid shifts
Note: The same studies ([6], [7], [8], [9], [11]) measured several electrolytes in the same patients. They are independent analytes but the same cohorts, so they are not independent confirmations of each other.
Calcium (orange)
Shares evidence with: Phosphate (red); Magnesium
Note: The calcium fall is described as secondary to the phosphate load [21][8]. The magnesium case report [21] is the same patient as the calcium case report, with a long QTc. Count it once.
Potassium; Calcium
Shares evidence with: Meta-analyses [5] and [6]
Note: Both meta-analyses pool sodium phosphate versus PEG trials and may include overlapping randomized trials; overlap was not checked. Do not treat them as two independent confirmations.
Phosphate (red)
Shares evidence with: Acute phosphate nephropathy (outcome, not a separate entry)
Note: The kidney outcome is described under the phosphate entry as a consequence of the excess. It is not a nutrient and is not double counted.
Gut microbiome (orange)
Shares evidence with: Fails verification: lasting dysbiosis and probiotic claims
Note: The same studies ([15], [17], [18], [20]) support the orange entry and rebut the lasting-damage claim. One evidence base, used in two places in opposite directions.
Mitochondrial burden; ATP production
Shares evidence with: Each other
Note: Both are ungraded because of the same search outcomes (the same Crossref, web search and rate-limited channels). One gap viewed twice, not two independent gaps.
Oxidative stress (yellow)
Shares evidence with: Mitochondrial burden; ATP production (ungraded)
Note: The rat MDA, SOD, GSH-Px and catalase readouts [26][27] are oxidative stress endpoints only. They are not counted toward mitochondrial or ATP entries. [26] and [27] are two separate rat experiments; the human thesis [28] is a third, independent line.
Copper; Iron; Oxygen delivery/utilization
Shares evidence with: Each other
Note: Ungraded on overlapping Crossref and web search queries (iron, copper, hemoglobin), and the two hemoglobin and hematocrit trials [29][30] are the only measured data touching both iron and oxygen delivery. No shared positive evidence exists; any oxygen-delivery effect would run through iron or fluid status and is not counted separately.

All references used above

Sodium phosphate (bowel prep)

Findings for this medication

What the research found

Phosphate: EXCESS load, acute, 1 to 2 day window

Potassium: transient hypokalemia in the prep window, resolving within about a week

Calcium: secondary transient fall that tracks the phosphate rise, not a dietary deficiency

Magnesium: label-named risk and one case report, no cohort measurement retrieved

Sodium and fluid shifts: mixed direction, magnitude not retrieved

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden

💥Oxidative Stress

Oxidative stress: local colonic tissue signal in rats, serum markers null in one small human trial

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk: short-term composition shift in a subgroup, mostly recovered by day 28

💨Oxygen and ATP Output

Oxygen delivery/utilization

ATP production

Claims checked and not supported

Gut microbiome: "bowel prep wipes out gut bacteria for good" (lasting dysbiosis)

Gut microbiome: "probiotics are needed after sodium phosphate prep"

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output